Effect of Busulfan in left ventricular global lingitudinal strain

Assessment of left ventricular function by global longitudinal strain to detect subclinical Cardiomyopathy early after Busulfan therapy in patients undergoing bone marrow allogeneic transplantation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191230045950N1

Enrollment

Registered

2020-01-18

Start date

2017-09-23

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy. Cardiomyopathy

Interventions

Intervention group:Echocardiograghy was done for Pateints undergoing bone marrow transplantation at the begining of the study and then 7 days after Busulfan therapy .Busulfan dose was 0.8 mg/kg wit

attaining 16 doses..

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing allogenic bone marrow transplantation

Exclusion criteria

Exclusion criteria: Diabetes melitus Hypertension Smoking Family history of Ischemic heart disease Major valvular heart disease Hyperlipidemia CKD Obesity Initial ejection fraction less than 55%

Design outcomes

Primary

Measure	Time frame
Left ventricular function by Global longitudinal strain (GLS). Timepoint: At the begining of the study and 7 days after Busulfan therapy. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Left ventricular end diastolic volume. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardoography.;Left ventricular end systolic volume. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardiography.;Left ventricular ejection fraction. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardiograghy.	—

Measure

Time frame

Left ventricular end diastolic volume. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardoography.;Left ventricular end systolic volume. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardiography.;Left ventricular ejection fraction. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardiograghy.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Yousef Qoddossi

Shahid Beheshti University of Medical Sciences

Qoddosi111@yahoo.com+98 21 2303 1111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026